Drugs / Aluminum Hydroxide Suspension
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07221162 Background | Dec 2025 → Nov 2026 expected | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aluminum Hydroxide Suspension | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07221162 ↗ |
| Route | Intramuscular | “Participants will be administered 5 micrograms of Boost-2867 with Alhydrogel (R) and CpG 7909 adjuvants, intramuscularly (IM), to previously vaccinated healthy adults.” NCT07221162 ↗ |